Cargando…
Spleen Tyrosine Kinase Inhibition Modulates p53 Activity
Spleen tyrosine kinase (SYK) is a cytoplasmic enzyme that promotes survival and proliferation of B cells. SYK inhibition has shown promising results in the treatment of arthritis and chronic lymphocytic leukemia (CLL). However, in other context, it has been shown that SYK overexpression in epithelia...
Autor principal: | Althubiti, Mohammad |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726622/ https://www.ncbi.nlm.nih.gov/pubmed/29249894 http://dx.doi.org/10.1177/1179066017731564 |
Ejemplares similares
-
Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers
por: Alwithenani, Akram I., et al.
Publicado: (2020) -
Tyrosine Kinase Targeting: A Potential Therapeutic Strategy for Diabetes
por: Althubiti, Mohammad
Publicado: (2022) -
Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase
por: Schweig, Jonas Elias, et al.
Publicado: (2017) -
Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases
por: Pamuk, Omer N, et al.
Publicado: (2010) -
Spleen tyrosine kinase inhibition restores myeloid homeostasis in COVID-19
por: Wigerblad, Gustaf, et al.
Publicado: (2023)